第八版AJCC分期下所有T1b黑色素瘤是否都应行前哨淋巴结活检?
该研究基于美国国家癌症数据库2015年黑色素瘤公共使用文件,纳入2010至2015年接受前哨淋巴结活检(SLNB)的厚度0.75至1.04 mm、无溃疡、按第八版AJCC厚度标准归为T1b的皮肤黑色素瘤患者6894例,评估SLNB阳性的临床病理危险因素。多因素分析显示年龄≤56岁、厚度1.0 vs 0.8-0.9 mm、女性、核分裂率≥1/mm2为独立危险因素;分类回归树分析识别出两个SLNB阳性风险<5%的组,占该人群55%。结论认为第八版AJCC的T1b分类不应单独用于决定薄黑色素瘤是否行SLNB。
要点
- 无溃疡T1b黑色素瘤中过半患者SLNB阳性风险<5%。
- 年龄≤56岁、女性、厚度1.0 mm、核分裂率≥1/mm2与SLNB阳性独立相关。
- 第八版AJCC仅凭厚度定义的T1b不宜直接决定SLNB。
核心结论
- 第八版AJCC黑色素瘤分期系统的T1b分类不应单独用于决定薄黑色素瘤是否行SLNB,因为超过一半无溃疡T1b病变SLNB阳性风险低。
研究设计与样本
- 回顾性队列研究,使用美国国家癌症数据库2015年黑色素瘤公共使用文件,纳入2010至2015年接受SLNB的厚度0.75至1.04 mm、无溃疡、按第八版AJCC厚度标准归为T1b的皮肤黑色素瘤患者6894例。
主要发现
- SLNB阳性的独立危险因素包括年龄≤56岁(OR 1.74;95%CI 1.38-2.17)、厚度1.0 vs 0.8-0.9 mm(OR 1.36;95%CI 1.09-1.70)、女性(OR 1.36;95%CI 1.09-1.69)、核分裂率≥1/mm2(OR 2.01;95%CI 1.54-2.64)。
- 分类回归树分析基于年龄、核分裂率和厚度识别出两个SLNB阳性风险<5%的组,这两组占接受SLNB的无溃疡T1b黑色素瘤患者的55%。
临床怎么用
- 临床决策中不应仅凭第八版AJCC的T1b分类对所有无溃疡薄黑色素瘤患者常规推荐SLNB,应结合年龄、核分裂率、厚度等风险因素个体化评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the 8th edition of the American Joint Committee on Cancer melanoma staging system, the T1b category has been redefined based solely on thickness and ulceration. National Comprehensive Cancer Network guidelines recommend consideration of sentinel lymph node biopsy (SLNB) for all patients with T1b melanomas (0.8 to 1.0 mm thick). We hypothesized that the new staging system would lead to excessive use of SLNB in patients with non-ulcerated T1b melanomas with a low risk of positive sentinel lymph nodes. STUDY DESIGN: The National Cancer Database 2015 Melanoma Public Use File was used to select patients undergoing SLNB for thin T1 cutaneous melanoma from 2010 to 2015. Clinicopathologic risk factors for having a positive SLNB were evaluated. Univariable and multivariable logistic regression models and classification and regression tree analysis were performed to identify groups with high and low risk of positive SLNB. RESULTS: We selected patients undergoing SLNB without ulceration with thickness 0.75 to 1.04 mm, staged T1b in the new 8th edition American Joint Committee on Cancer by thickness criteria alone (6,894 patients). Independent risk factors for a positive sentinel lymph node were age 56 years or younger (odds ratio [OR] 1.74; 95% CI 1.38 to 2.17), thickness 1.0 vs 0.8 to 0.9 mm (OR 1.36; 95% CI 1.09 to 1.70), female sex (OR 1.36; 95% CI 1.09 to 1.69), and mitotic rate ≥1/mm2 (OR 2.01; 95% CI 1.54 to 2.64). Classification and regression tree analysis identified 2 groups based on age, mitotic rate, and thickness with a risk of positive SLNB <5%. These 2 groups made up 55% of T1b, nonulcerated melanoma patients who underwent SLNB. CONCLUSIONS: The new 8th edition American Joint Committee on Cancer melanoma staging system T1b category should not be used to determine use of SLNB in thin melanoma, as more than one half of T1b lesions without ulceration have a low risk of positive sentinel lymph nodes.
引用
- Egger ME, Stevenson M, Bhutiani N, et al. Should Sentinel Lymph Node Biopsy Be Performed for All T1b Melanomas in the New 8th Edition American Joint Committee on Cancer Staging System? J Am Coll Surg. 2019. PMID: 30660817. doi:10.1016/j.jamcollsurg.2018.12.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。